Role of Calcium Binding Protein S100A12 in Diagnosis and Prognosis of Kawasaki Disease
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 100
- Primary Endpoint
- S100A12
Study Overview
Brief Summary
Recent studies showed that the value of c100A12 increased in children with Kawasaki disease, and decreased rapidly after treatment with gamma globulin. In kawasaki disease with coronary artery dilatation, S100A12 levels are elevated in the acute phase of Kawasaki disease and continue for some time in the convalescence phase before gradually decreasing. However, the number of patients included in previous studies was small and the follow-up time was short. In this study, 100 children with Kawasaki disease who were admitted to Wuhan Children's Hospital, Jingzhou First People's Hospital and Renhe Hospital affiliated to China Three Gorges University from December 2021 to December 2023 were selected as the research objects, and 100 children with healthy physical examination were selected as the control group during the same period. To investigate whether S100A12 increased significantly in the acute phase of Kawasaki disease compared with a healthy control group. To study whether S100A12 value increased rather than decreased in kawasaki disease that did not respond to gamma globulin treatment after gamma globulin treatment. At the same time, to study whether the increase of S100A12 in kawasaki disease convalescence indicates coronary aneurysm.
Detailed Description
S100A12 was determined using the ELISA kit and according to the instructions.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Retrospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •▪Diagnostic criteria of Kawasaki disease revised by the American Heart Association in 2017
Exclusion Criteria
- •Scarlet fever
- •Drug allergy syndrome
- •Stevens-Johnson syndrome
- •Toxic shock syndrome
- •Adenovirus infection
- •Epstein-Barr(EB) virus infection
Outcomes
Primary Outcomes
S100A12
Time Frame: From date of randomization until the date of first documented progression, whichever came first, assessed up to 18 months
S100A12 was increased in children with Kawasaki disease and decreased after gamma globulin treatment
Secondary Outcomes
- CRP(From date of randomization until the date of first documented progression, whichever came first, assessed up to 18 months)
Investigators
Pan Yan
Attending physician
The First Affiliated Hospital of Yangtze University